-DOCSTART- -X- O
INTRODUCTION -X- _ O
: -X- _ O
The -X- _ O
overall -X- _ O
outcome -X- _ O
of -X- _ O
septic -X- _ O
shock -X- _ O
has -X- _ O
been -X- _ O
recently -X- _ O
improved. -X- _ O
We -X- _ O
sought -X- _ O
to -X- _ O
determine -X- _ O
whether -X- _ O
this -X- _ O
survival -X- _ O
gain -X- _ O
extends -X- _ O
to -X- _ O
the -X- _ O
high-risk -X- _ O
subgroup -X- _ O
of -X- _ O
patients -X- _ B-Patient
with -X- _ I-Patient
cirrhosis. -X- _ I-Patient
METHODS -X- _ O
: -X- _ O
Cirrhotic -X- _ O
patients -X- _ O
with -X- _ O
septic -X- _ O
shock -X- _ O
admitted -X- _ O
to -X- _ O
a -X- _ O
medical -X- _ O
intensive -X- _ O
care -X- _ O
unit -X- _ O
( -X- _ O
ICU -X- _ O
) -X- _ O
during -X- _ O
two -X- _ O
consecutive -X- _ O
periods -X- _ O
( -X- _ O
1997-2004 -X- _ O
and -X- _ O
2005-2010 -X- _ O
) -X- _ O
were -X- _ O
retrospectively -X- _ O
studied. -X- _ O
RESULTS -X- _ O
: -X- _ O
Forty-seven -X- _ B-Patient
and -X- _ I-Patient
42 -X- _ I-Patient
cirrhotic -X- _ I-Patient
patients -X- _ I-Patient
presented -X- _ O
with -X- _ O
septic -X- _ O
shock -X- _ O
in -X- _ O
1997-2004 -X- _ O
and -X- _ O
2005-2010 -X- _ O
, -X- _ O
respectively. -X- _ O
The -X- _ O
recent -X- _ B-Outcome
period -X- _ I-Outcome
differed -X- _ I-Outcome
from -X- _ I-Outcome
the -X- _ I-Outcome
previous -X- _ I-Outcome
one -X- _ I-Outcome
by -X- _ I-Outcome
implementation -X- _ I-Outcome
of -X- _ I-Outcome
adjuvant -X- _ I-Outcome
treatments -X- _ I-Outcome
of -X- _ I-Outcome
septic -X- _ I-Outcome
shock -X- _ I-Outcome
including -X- _ I-Outcome
albumin -X- _ I-Outcome
infusion -X- _ I-Outcome
as -X- _ I-Outcome
fluid -X- _ I-Outcome
volume -X- _ I-Outcome
therapy -X- _ I-Outcome
, -X- _ I-Outcome
low-dose -X- _ I-Outcome
glucocorticoids -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
intensive -X- _ I-Outcome
insulin -X- _ I-Outcome
therapy. -X- _ I-Outcome
ICU -X- _ I-Outcome
and -X- _ I-Outcome
hospital -X- _ I-Outcome
survival -X- _ I-Outcome
markedly -X- _ I-Outcome
improved -X- _ I-Outcome
over -X- _ I-Outcome
time -X- _ I-Outcome
( -X- _ I-Outcome
40 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
2005-2010 -X- _ I-Outcome
vs. -X- _ I-Outcome
17 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
1997-2004 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.02 -X- _ I-Outcome
and -X- _ I-Outcome
29 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
2005-2010 -X- _ I-Outcome
vs. -X- _ I-Outcome
6 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
1997-2004 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.009 -X- _ I-Outcome
, -X- _ I-Outcome
respectively -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Furthermore -X- _ I-Outcome
, -X- _ I-Outcome
this -X- _ I-Outcome
survival -X- _ I-Outcome
gain -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
latter -X- _ I-Outcome
period -X- _ I-Outcome
was -X- _ I-Outcome
sustained -X- _ I-Outcome
for -X- _ I-Outcome
6 -X- _ I-Outcome
months -X- _ I-Outcome
( -X- _ I-Outcome
survival -X- _ I-Outcome
rate -X- _ I-Outcome
24 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
2005-2010 -X- _ I-Outcome
vs. -X- _ I-Outcome
6 -X- _ I-Outcome
% -X- _ I-Outcome
in -X- _ I-Outcome
1997-2004 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.06 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
After -X- _ I-Outcome
adjustment -X- _ I-Outcome
with -X- _ I-Outcome
age -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
liver -X- _ I-Outcome
disease -X- _ I-Outcome
stage -X- _ I-Outcome
( -X- _ I-Outcome
Child-Pugh -X- _ I-Outcome
score -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
the -X- _ I-Outcome
critical -X- _ I-Outcome
illness -X- _ I-Outcome
severity -X- _ I-Outcome
score -X- _ I-Outcome
( -X- _ I-Outcome
SOFA -X- _ I-Outcome
score -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
ICU -X- _ I-Outcome
admission -X- _ I-Outcome
between -X- _ I-Outcome
2005 -X- _ I-Outcome
and -X- _ I-Outcome
2010 -X- _ I-Outcome
remained -X- _ I-Outcome
an -X- _ I-Outcome
independent -X- _ I-Outcome
favorable -X- _ I-Outcome
prognostic -X- _ I-Outcome
factor -X- _ I-Outcome
( -X- _ I-Outcome
odds -X- _ I-Outcome
ratio -X- _ I-Outcome
( -X- _ I-Outcome
OR -X- _ I-Outcome
) -X- _ I-Outcome
0.09 -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
confidence -X- _ I-Outcome
interval -X- _ I-Outcome
( -X- _ I-Outcome
CI -X- _ I-Outcome
) -X- _ I-Outcome
0.02-0.4 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.004 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
The -X- _ I-Outcome
stage -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
underlying -X- _ I-Outcome
liver -X- _ I-Outcome
disease -X- _ I-Outcome
was -X- _ I-Outcome
also -X- _ I-Outcome
independently -X- _ I-Outcome
associated -X- _ I-Outcome
with -X- _ I-Outcome
hospital -X- _ I-Outcome
mortality -X- _ I-Outcome
( -X- _ I-Outcome
Child-Pugh -X- _ I-Outcome
score -X- _ I-Outcome
: -X- _ I-Outcome
OR -X- _ I-Outcome
1.42 -X- _ I-Outcome
per -X- _ I-Outcome
point -X- _ I-Outcome
, -X- _ I-Outcome
95 -X- _ I-Outcome
% -X- _ I-Outcome
CI -X- _ I-Outcome
1.06-1.9 -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
= -X- _ I-Outcome
0.018 -X- _ I-Outcome
) -X- _ O
. -X- _ O
CONCLUSIONS -X- _ O
: -X- _ O
In -X- _ O
the -X- _ O
light -X- _ O
of -X- _ O
advances -X- _ O
in -X- _ O
management -X- _ O
of -X- _ O
both -X- _ O
cirrhosis -X- _ O
and -X- _ O
septic -X- _ O
shock -X- _ O
, -X- _ O
survival -X- _ O
of -X- _ O
such -X- _ O
patients -X- _ O
substantially -X- _ O
increased -X- _ O
over -X- _ O
recent -X- _ O
years. -X- _ O
The -X- _ O
stage -X- _ O
of -X- _ O
the -X- _ O
underlying -X- _ O
liver -X- _ O
disease -X- _ O
and -X- _ O
the -X- _ O
related -X- _ O
therapeutic -X- _ O
options -X- _ O
should -X- _ O
be -X- _ O
included -X- _ O
in -X- _ O
the -X- _ O
decision-making -X- _ O
process -X- _ O
for -X- _ O
ICU -X- _ O
admission -X- _ O
. -X- _ O

